Uth M, Curtin NJ, Helleday T: Particular killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434(7035):91317. 2. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic approach. Nature 2005, 434(7035):91721. three. Dobzhansky T: Genetics of natural populations. Xiii. Recombination and variability in populations of Drosophila Pseudoobscura. Genetics 1946, 31(three):26990. four. Lucchesi JC: Synthetic lethality and semi-lethality among functionally connected mutants of Drosophila melanogaster. Genetics 1968, 59(1):374. 5. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Pal SH: Integrating genetic approaches into the discovery of anticancer drugs. Science 1997, 278(5340):1064068. 6. Kaelin WG Jr: The notion of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005, five(9):68998. 7. Rehman FL, Lord CJ, Ashworth A: Synthetic lethal approaches to breast cancer therapy. Nat Rev Clin Oncol 2010, 7(12):71824. eight. Fong Computer, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O’Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361(2):12334.9.ten.11.12. 13. 14.15.16.17.18. 19. 20. 21. 22. 23.24.25.26. 27.28.29.Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, Wardley A, Mitchell G, Earl H, Wickens M, Carmichael J: Oral poly(ADP-ribose) polymerase inhibitor olaparib in sufferers with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376(9737):23544. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.Dehydroepiandrosterone sulfate Lancet Oncol 2011, 12(9):85261.Toceranib Balma J, Domchek SM, Tutt A, Garber JE: Stumbling blocks on the path to customized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. Cancer Discov 2011, 1(1):294. Davar D, Beumer JH, Hamieh L, Tawbi H: Part of PARP inhibitors in cancer biology and therapy. Curr Med Chem 2012, 19(23):3907921. Lord CJ, Ashworth A: The DNA harm response and cancer therapy.PMID:24883330 Nature 2012, 481(7381):28794. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, Giavara S, O’Connor MJ, Tutt AN, Zdzienicka MZ, Smith GC, Ashworth A: Deficiency inside the repair of DNA harm by homologous recombination and sensitivity to poly (ADP-ribose) polymerase inhibition. Cancer Res 2006, 66(16):8109115. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, Rayter S, Tutt AN, Ashworth A: A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 2008, 27(9):1368377. Williamson CT, Muzik H, Turhan AG, ZamA, O’Connor MJ, Bebb DG, Lees-Miller SP: ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010, 9(two):34757. Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PA, Taylor AM, Stankovic T: T.
